An Updated Systematic Review and Meta-Analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation, Adverse effects and other Clinical Outcomes of Ivermectin Treatment in COVID-19 Patients

**Smruti Karale, MBBS[1]; *Vikas Bansal, MBBS, MPH[2]; Janaki Makadia, MBBS[3]; Muhammad Tayyeb, MD[4]; Hira Khan, MBBS[5]; Shree Spandana Ghanta, MBBS[6]; Romil Singh, MBBS[7]; Aysun Tekin, MD[8]; Abhishek Bhurwal, M9[8]; Hemant Mutneja, MD[10]; Ishita Mehra, MBB[11]; Rahul Kashyap, MBBS, MBA[8]*

[1]Medical Graduate, Government Medical College Kolhapur, Kolhapur, India

[2]Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, MN, USA

[3]Medical Graduate, GMERS Medical College, Vadodara, Gujarat, India

[4]Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ, USA

[5]Department of Neurology, Allegheny General Hospital, Pittsburgh, PA, USA

[6]Department of Internal Medicine, St. Elizabeth's Medical Center, Boston, MA, USA

[7]Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA

[8]Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Rochester, MN, USA

[9]Department of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, USA

[10]Division of Gastroenterology, Cook County Hospital, Chicago, Illinois

[11]Department of Internal Medicine, North Alabama Medical Center, Florence, AL, USA

Corresponding Author:

Vikas Bansal, MBBS, MPH

Assistant Professor of Medicine

Division of Pulmonary and Critical Care Medicine

Mayo Clinic, Rochester, MN- 55905

Email: bansal.vikas@mayo.edu

Phone: +1-507-398-1595

Word count: Abstract: 250; Manuscript: 5041

Tables: 0 main, 8 supplemental

Figures: 6 main, 31 supplemental

Conflicts of Interest: None of the authors have reported any conflicts of interest.

Financial Support: There is no financial disclosure related to this study.

Author Contribution: *Authors 1(SK) and 2(VB) contributed equally in defining the study outline and manuscript writing. Data review and collection were done by HK, JM, SG, RS, SK, and MT; statistical analysis done by SK, VB, and AB. Quality assessment of studies was done by AT,JM, HK, MT, SK, VB and GRADE quality rating was done by AB, HM and VB. Study design, distribution of articles for critical review done by SK, VB and RK. Final approval was received from all authors. SK and VB is the guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to published article.

Acknowledgment: We acknowledge Dr. Anant Mohan, Dr. Asma Asghar, Dr. Flavio Cadegiani, Dr. Houssam Raad, Dr. José Morgenstern, Dr. Morteza Niaee, Dr. Nasir Afsar, Dr. Nurullah Okumus, Dr. Olufemi Babalola, Dr. Pablo Méndez-Hernández, Dr. Ravi Kirti, Dr.Ravindra Ghooi, Dr. Reaz Mahmud and Dr. Tasnim Ahsan for their correspondence and contribution.

Keywords: Ivermectin, COVID-19, SARS-CoV-2, Mortality, ICU, Mechanical ventilation, adverse effect, Systematic Review, Meta-analysis

Short tile: Clinical Outcomes Associated with Ivermectin use in COVID-19: An Updated Systematic Review And Meta-Analysis

Highlights

What We Already Know about This Topic

1. COVID-19 is an ongoing global pandemic, for which Ivermectin has been tried on a therapeutic and prophylactic basis.
2. Results from several clinical trials and observational studies suggest that Ivermectin may improve survival and clinical outcomes with a good safety profile when compared with other treatments; however, the current evidence is limited. .

What This Article Tells Us That Is New

1. This systematic review and meta-analysis provide a summary of the latest literature on the efficacy and safety of Ivermectin use for COVID-19.
2. Based on our analysis of the latest evidence, we found that Ivermectin's benefit in reducing mortality cannot be concluded with confidence . However, as an adjuvant

therapy it may help reduce the need for hospitalization, duration for viral clearance while increasing the likelihood of achieving viral clearance.

3. We need more high-quality data for conclusive evidence regarding the benefit of Ivermectin in reducing the need for ICU admissions ,mechanical ventilation and duration of hospital stay in COVID-19 patients.

List of abbreviations

ARDS: Acute respiratory distress syndrome

CDC: Centers for Disease Control and Prevention

COVID-19: Coronavirus Disease 2019

DNA: Deoxyribonucleic Acid

EMA: European Medicines Agency

FDA: Food and Drug Administration

ICU: Intensive Care Unit

IRB: Institutional Review Board

NIH: National Institutes of Health

RCT: Randomized controlled trial

RNA: Ribonucleic Acid

RT-PCR: Reverse Transcription Polymerase Chain Reaction

IMP: Importin

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

WHO: World Health Organization

Abstract

Importance: Repurposing Ivermectin, a known anti-parasitic agent, for treating COVID-19 has demonstrated positive results in several studies. We aim to evaluate the benefit and risk of Ivermectin in COVID-19.

Methods: We conducted a systematic search for full-text manuscripts published from February 1, 2020, to August 15th, 2021 focusing on Ivermectin therapy against COVID-19. The primary outcomes were mortality, need for intensive care unit (ICU) admission; secondary outcomes were - adverse effects, need for mechanical ventilation, viral clearance, time to viral clearance, need for hospitalization, and length of hospital stay. Random-effects models were used for all analyses.

Results: We included a total of 52 studies (n=17561) in the qualitative analysis, out of these, 44 studies (n=14019) were included in the meta-analysis. In the mortality meta-analysis (N=29), odds of death were lower in the Ivermectin-arm compared to control (OR 0.54, p=0.009). Although lower odds of mortality were observed in various subgroup analyses of RCTs, they did not reach statistical significance: therapeutic RCTs: mild-moderate COVID-19 (OR 0.31, p=0.06), therapeutic RCTs: severe/critical COVID-19 (OR 0.86, p=0.56), inpatient RCTs: mild-moderate COVID-19 (OR 0.18, p=0.08), inpatient RCTs: severe/critical COVID-19 (OR 0.86, p=0.56). Ivermectin, mostly as adjuvant therapy, was associated with higher odds of viral clearance (N=22) (OR 3.52, p=0.0002), shorter duration to achieve viral clearance (N=8) (MD -4.12, p=0.02), reduced need for hospitalization (N=6) (OR 0.34, p=008).

Conclusion: Our meta-analysis suggests that the mortality benefit of Ivermectin in COVID-19 is uncertain. But as adjuvant therapy, Ivermectin may improve viral clearance and reduce the need for hospitalization.

Introduction

On March 11, 2020, the World Health Organization (WHO) declared COVID-19 disease a global pandemic[1]. Today, on September 9,2021, there are about >222 million confirmed cases worldwide and >4.6 million deaths due to COVID-19[2]. Patients infected with SARS-COV-2, the causative Coronavirus, exhibit a spectrum of clinical presentations ranging from asymptomatic to severely critical and multiple risk factors are involved in the prognosis of the disease[3-8]. To guide decision-making for this multi-system disease[8-17], a variety of treatment modalities have been proposed and evaluated[18-23]. However, the evidence for the risk-benefit ratio of most of these treatments remains unclear.

Ivermectin has held an excellent safety record in humans as an antiparasitic agent for over three decades[24]. Apart from its established activity against several parasites, Ivermectin has demonstrated antiviral activity against many RNA and DNA viruses in vivo and against a few in vitro by targeting specific proteins[25]. One such plausible mechanism against RNA viruses is the inhibition of importin (IMP) α/β Integrase , thus blocking viral entry into the nucleus and the ensuing suppression of the cell's anti-viral response[25-28]. Moreover, it exhibited anti-bacterial, anti-inflammatory, and anti-cancer effects[24,29,30]. An Australian study demonstrated the effectiveness of Ivermectin in inhibiting SARS-COV2 in-vitro[31]. Subsequently, several Ivermectin-based clinical trials and observational studies conducted globally showed mostly positive results[32-35]. Some countries have incorporated this therapy in their COVID-19 guidelines[36-39]. Only a month after this authorization, Peru witnessed a record drop of 25% in COVID-19 related mortality[40].

Dr. Satoshi Ōmura, who was among the scientists that won the Nobel prize for the discovery of Ivermectin, highlighted the need to develop a drug that arrests the early stage of

viral replication in COVID-19[41]. Repurposing Ivermectin, a low-cost drug may help bypass the time and funds needed to develop and test novel therapies. The lack of robust evidence has been a major hindrance in the large-scale approval of Ivermectin. The available studies are methodologically diverse and mostly under-powered while few report conflicting results. Therefore, we intend to systematically review the latest literature and plan to perform a meta-analysis to overcome some of the individual study biases.

Methods:

Search Method and strategy

We conducted a comprehensive literature search for studies mentioning the use of Ivermectin in COVID-19 from February 1, 2020 till August 15, 2021 (Figure 1). We screened all titles and abstracts identified by preliminary search for eligible studies and manually searched references of included articles for additional studies. Then we analyzed full-text manuscripts of included studies according to the protocol of Systematic Review and Meta-Analysis (PRISMA) guidelines.

Eligibility Criteria

We included studies reporting outcomes of mortality, ICU admission, mechanical ventilation, adverse-effects, viral clearance, hospitalization with therapeutic Ivermectin treatment against COVID-19. We excluded studies focusing on pregnant females, in- vitro studies, meta-analyses, case reports and case series <5 patients.

Study selection and data extraction

The extracted data was tabularized in Microsoft Excel with following parameters: author, country of study, study design, number of patients, Ivermectin regimen, concomitant treatment, efficacy outcomes and adverse effects. The included data was checked for accuracy by all

authors and disagreements were resolved through consensus and after input from a third reviewer. IRB approval was exempted because data was extracted from publicly available studies. We also analyzed raw data files or supplemental files of studies by Cadegiani[42] and Lima-Morales et al[43] for outcomes of cases receiving Ivermectin, Niaee et al[44] for clinical severity based mortality data and duration of hospital stay, Choudhary et al[35] for time for viral clearance, Mahmud et al[45] for need for hospitalization, Ghooi et al[46] for mortality in Ivermectin receiving patients, Samaha et al[47] for viral clearance. In Cadegiani et al's study[42], we considered 'CG1' as control group because only this sample was demographically comparable to the treatment group. Additionally, we compiled all ongoing clinical trials on Ivermectin from clinicaltrials.gov (e-Table-8). We excluded the study by Elgazzar et al[48] because it was retracted.

Outcomes

The primary outcome was defined as mortality benefit with Ivermectin therapy in COVID-19 and need for ICU admission. The secondary outcomes were need for mechanical ventilation ,adverse effects of Ivermectin, viral clearance and time to achieve viral clearance, need for hospitalization and duration of hospital stay.

Statistical analysis

Primary and Secondary outcomes were quantitatively analyzed by Review Manager (RevMan) Version 5.4 for windows[49] and Comprehensive Meta-Analysis software package (Biostat, Englewood, NJ, USA)[50] was used for pooled-analysis. Random-effects model was used for both[51]. Raw data for outcomes and non-events from each study were used to calculate crude odds ratio (OR) with 95% confidence intervals (CI) for each study. The Cochrane Q and I^2 statistics were calculated to assess heterogeneity between studies[51]. I^2 <25% were interpreted as low-level heterogeneity[51]. We performed subgroup analysis by study design to decrease inherent

selection bias in observational studies[51]. Probability of publication bias was assessed with funnel plot using Egger's tests[51] (e-Figure 15-31). If there was statistical heterogeneity in results, further sensitivity analysis was conducted to determine the source of heterogeneity by excluding each study. After significant heterogeneity was excluded, random-effects model was used for meta-analysis. For sensitivity analysis, if we found heterogeneity to be similar with different studies' exclusion, we chose to present the result with lowest odd's ratio. P-value <0.05 (2-sided) was considered statistically significant[51].

Risk of Bias and Quality assessment

Clinical trials were evaluated using Cochrane risk of bias tool[52] (e-Table 2) and correlation of quality measures with estimates of treatment effects in meta-analyses of randomized controlled trials tool[53] (e-Table 3) was used for quality assessment. We used NIH quality assessment Tool for case series[54] (e-Table 4), case-control (e-Table 5), or cohort studies (e-Table 6). NIH quality assessment tools were based on quality assessment methods, concepts, and other tools developed by researchers in the Agency for Healthcare Research and Quality (AHRQ), Cochrane Collaboration, USPSTF, Scottish Intercollegiate Guidelines Network, and National Health Service Centre for Reviews and Dissemination, consulting epidemiologists and evidence-based medicine experts, with adaptations by methodologists and NHLBI staff. We assessed the certainty of evidence by using GRADE pro profiler[55] (GRADE working group, McMaster University and Evidence Prime Inc) at the outcome level (e-Table 7).

Results

Study Characteristics

A total of 17561 patients from 52 articles[32-35,42-47,56-97] (Ivermectin n=7509, No Ivermectin n= 10052) were included in the pooled analysis , 14019 patients from 44 studies

(Ivermectin n=3913, No Ivermectin n=10106) were included in quantitative synthesis (e-Table 1, Figure 1). Out of 33 trials, 26 were true RCTs (e-Table 1, Figure 1). The remaining 19 studies were observational and included 6 case-series (e-Table 1, Figure 1). Out of 52, 13 articles were available as preprints, Huvemec trial[76] details were obtained online and clinicaltrials.gov was used for data extraction for 1 trial[65] (e-Table 1, Figure 1). Due to absence of informed consent, blinding and randomization, we considered Veerapaneni et al's[93] study as case control study.

Primary Outcomes

(A) Mortality

Meta-analysis Overall

Total 29 studies reported mortality rate in patients receiving Ivermectin (279/3240) vs no-Ivermectin therapy (1347/9407). The odds of mortality in the Ivermectin group were lower compared to control group but the heterogeneity was high (OR 0.54, 95% CI 0.34-0.86, p=0.009; I^2=75%) (Figure 2A). Evidence was graded very low (e-table 7). In sensitivity analysis, we observed similar mortality benefit with moderate heterogeneity after excluding study by Soto-Becerra et al[92] (OR 0.49, 95% CI 0.32-0.75, p=0.001; I^2=52%) (Figure 2B).

Subgroup analysis by study design

Subgroup: Clinical trials

We performed subgroup analysis of 18 clinical trials (RCTs N=15, Non-RCTs N=3) and observed similar mortality benefit (OR 0.47, 95% CI 0.25-0.90, p=0.02; I^2=59%) (Figure 3A) but evidence was graded low (e-table 7). On excluding Lima-Morales et al[43] for sensitivity analysis, benefit was observed with low heterogeneity but was not statistically significant (OR 0.61, 95% CI 0.37-1.02, p=0.06; I^2=19%) (e-Figure 1).

Subgroup: RCTs

We analyzed clinical severity-based data in 15 RCTs which included patients treated with Ivermectin on inpatient or outpatient basis. In the mild/moderate subgroup, the odds of mortality were lower with moderate heterogeneity but did not reach statistical significance (OR 0.31, 95% CI 0.09-1.04, p=0.06; I^2=45%) (Figure 3B). Similarly, mortality benefit was not statistically significant in the severe/critical subgroup (OR 0.86, 95% CI 0.51-1.45, p=0. 56; I^2=0%) (Figure 3C). Certainty of evidence was low in the mild/moderate and severe/critical subgroup (e-table 7).

In sensitivity analysis, after excluding Vallejos et al[96] from the mild-moderate subgroup, the odds of mortality decreased with low heterogeneity and reached statistical significance (OR 0.21, 95% CI 0.06-0.69, p=0.01; I^2=24%) (e-Figure 2). Therefore, in mild/moderate COVID-19 patients, Ivermectin may possibly be useful for reducing mortality when we used as an adjuvant therapy.

Observational studies

Mortality benefit was not statistically significant in subgroup analysis of 11 observational studies (OR 0.64, 95% CI 0.35-1.16, p=0.14; I^2=73%) (Figure 3D) and evidence was graded very low (e-table 7). After excluding Soto-Becerra et al[92] in sensitivity analysis, we observed statistically significant mortality benefit with moderate heterogeneity (OR 0.54, 95% CI 0.32-0.92, p=0.02; I^2=38%) (e-Figure 3).

Subgroup analysis for hospitalized patients

Overall

In the subgroup analysis for hospitalized patients (studies N=18) mortality benefit was not statistically significant (OR 0.65, 95% CI 0.42-1.00, p=0.05; I^2=66%) (Figure 3E). Evidence was very low (e-table 7). After excluding Soto-Becerra et al[92] in sensitivity analysis, we

observed statistically significant lower odds of mortality with moderate heterogeneity (OR 0.58, 95% CI 0.39-0.87, p=0.008; I^2=37%) (e-Figure 4).

Subgroup: Inpatient RCTs

We analyzed clinical severity-based data in 9 RCTs with only hospitalized patients. It showed mortality benefit that was not statistically significant in the mild-moderate COVID-19 subgroup (OR 0.18, 95% CI 0.02-1.25, p=0.08; I^2=61%) (Figure 3F) and in the severe/critical COVID-19 subgroup (OR 0.86, 95%CI 0.51-1.45, p=0.56; I^2=0%) (Figure 3G). Evidence was graded low in both the subgroup analyses (e-table 7). After excluding Abd-elsalam et al[94] in sensitivity analysis for mild-moderate COVID-19, mortality benefit was statistically significant (OR 0.06, 95% CI 0.01-0.33, p=0.001; I^2= 0%) (e-Figure 5).

Subgroup: Inpatient Observational studies

In the analysis of 8 observational studies with only hospitalized patients, significant mortality benefit was not seen, and heterogeneity was high (OR 0.70, 95% CI 0.38-1.30, p=0.26; I^2=77%) (Figure 3H). Evidence was graded very low (e-table 7). In sensitivity analysis, after excluding Soto-Becerra et al[92] no significant mortality benefit was seen and heterogeneity was moderate (OR 0.58, 95% CI 0.32-1.05, p=0.07; I^2=50%) (e-Figure 6).

(B) Effect of Ivermectin monotherapy compared with Placebo/Standard of Care as per Cochrane's criteria

We identified 7 RCTs where they investigated the effect of ivermectin monotherapy with or without standard of care compared to placebo or standard of care. Overall, no significant mortality benefit was observed (OR 0.75, 95%CI 0.35-1.63, p=0.47; I^2=0%) (Figure 4). In severity based subgroup analysis, the result remained same for mild/moderate subgroup (OR 0.71, 95% CI 0.27-1.87, p=0.49; I^2=0%) and severe/critical subgroup (OR 0.83, 95% CI 0.23-

3.02, p=0.78; I^2=NA) (Figure 4). Certainty of evidence was moderate overall and in the mild/moderate subgroup, however it was graded low in severe/critical subgroup due to small sample size (e-table 7).

Pooled Analysis for mortality

Pooled analysis of 37 studies out of 52 studies, yielded a rate of 3.6%, 95% CI 2.1-6.3; I^2=93.87% (e-Figure 7).

(C) Need for ICU admission

Meta-analysis

In 5 studies (out of 52), 27/263 in the Ivermectin arm, 52/322 in the control arm needed ICU admission. Benefit with Ivermectin was not statistically significant (OR 0.48, 95% CI 0.17-1.37, p=0.17; I^2=59%) (Figure 5A). Evidence was graded very low (e-table 7). In sensitivity analysis, after excluding Galan et al[71] we observed statistically significant benefit (OR 0.32, 95% CI 0.11-0.92, p=0.03; I^2=27%) (Figure 5B). Based on low grading of evidence and observed low-moderate heterogeneity in analysis, Ivermectin may be helpful in combination therapy in decreasing need for ICU admission. Further validation with well-designed pragmatic platform trials is needed.

Pooled Analysis

Pooled ICU admission rate obtained from 8 studies out of 52 studies was 5.4%, 95% CI 1.9-14.7; I^2=91.9% (e-Figure 8).

Secondary Outcomes

(A) Need for Mechanical Ventilation

Meta-analysis

Overall, 12 studies documented the need for mechanical ventilation. 71/1362 patients receiving Ivermectin and 88/1154 patients in the control arm required mechanical ventilation. The benefit of Ivermectin was not statistically significant (OR=0.75, 95%CI 0.52-1.08, p=0.12; I^2=0%) (Figure 5C). Evidence was graded very low (e-table 7). On excluding Galan et al[71] in sensitivity analysis, benefit observed was not statistically significant and showed no heterogeneity (OR 0.68, 95% CI 0.45-1.01, p=0.06; I^2=0%) (Figure 5D).

Pooled Analysis

The rate of need for mechanical ventilation based on 14 studies (out of 52 studies) was 3.9%, 95% CI 1.7-8.6; I^2=87.2% (e-Figure 9).

(B) Adverse events

Meta-analysis

A total of 22 studies reported data for rate of adverse-events in the Ivermectin-arm (292/1405) vs control group (288/1372). We did not find an association between Ivermectin and rate of adverse events as compared to controls (OR 0.87, 95% CI 0.67- 1.13, p=0.30; I^2=1%). (Figure 5E) but evidence was graded very low (e-table 7). In sensitivity analysis, after excluding Veerapaneni et al[93] incidence of adverse effects with Ivermectin was similar to that of the control group but was not conclusive (OR 0.84, 95% CI 0.65-1.08, p=0.18; I^2=0%) (Figure 5F).

Pooled Analysis

A total of 38 studies (out of 52 studies) yielded a pooled rate of 6.6%, 95% CI 3.9-11.1; I^2=92.2% (e-Figure 10).

(C) Viral Clearance

Twenty-two studies reported data for patients achieving viral clearance: 1036/1327 in the Ivermectin arm while 790/1206 patients in the non-Ivermectin arm tested negative for RT-PCR. The analysis indicated that patients in the Ivermectin-arm showed higher odds of achieving viral clearance when compared to the control group at a given point in time (OR 3.52,95%CI 1.81-6.86, $p<0.01$; $I^2=85\%$) (figure 6A). Evidence level was low (e-table 7). When we excluded Mourya et al[85] in the sensitivity analysis, similar benefit was observed but heterogeneity remained high (OR 2.79, 95%CI 1.52-5.10, $p<0.01$; $I^2=81\%$) (e-figure 11).

(D) Time to achieve Viral Clearance

Eight studies presented data for the time needed for viral clearance in the Ivermectin receiving arm vs that in the non-Ivermectin arm. The results show that the time needed to achieve viral clearance was shorter by over 4 days in the Ivermectin group as compared to the non-Ivermectin group, but with high heterogeneity (MD -4.12,95%CI -7.59,-0.65, $p=0.02$; $I^2=98\%$) (figure 6B). Evidence level was low (e-table 7). In sensitivity analysis, benefit was seen but heterogeneity remained high after excluding Khan et al's study[77] (MD -3.24, 95%CI -5.37,-1.10, $p=0.003$; $I^2=92\%$) (e-figure 12).

(D) Need for hospitalization

Six studies described information for the number of patients requiring hospitalization when receiving Ivermectin (113/1074) as compared to those not receiving it (212/947). As per the analysis, Ivermectin group showed lower need for hospitalization as compared to controls but with high heterogeneity (OR 0.34, 95%CI 0.16-0.75, $p=0.008$; $I^2=78\%$) (Figure 6C). Evidence was low grade (e-table 7). On excluding Lima Morales et al[43] in sensitivity analysis, similar

benefit was seen with moderate heterogeneity but without statistical significance (OR 0.43, 95% CI 0.18-1.01, p=0.05; I^2=59%) (e-figure 13).

(F) Length of hospital stay

We analyzed data from 9 studies regarding the duration of hospital stay in the Ivermectin vs control arm. In this meta-analysis, we found that the benefit of Ivermectin in reducing the duration of hospital stay was not statistically significant and heterogeneity was high (MD -1.80, 95% CI -3.69,0.08, p= 0.06; I^2=94%) (Figure 6D). Evidence was low grade (e-table 7). In the sensitivity analysis, we excluded Khan et al's study[72] and the duration of hospital stay was shorter by one day in the Ivermectin arm compared to non-Ivermectin arm with high heterogeneity and no statistical significance (MD -1.16, 95%CI -2.42,-0.1, p=0.07; I^2=84%) (e-figure 14).

Discussion

Our meta-analysis suggests that the role of Ivermectin in improving patient survival in COVID-19 is uncertain. However, Ivermectin might help more patients achieve viral clearance, in a shorter duration of time and may also help reduce the need for hospitalization when used in combination therapy. Its benefit in reducing the need for admission to the ICU, mechanical ventilation and the duration of hospital stay cannot be concluded with confidence. Its relation to the incidence of adverse effects is inconclusive. Further, our pooled analysis indicates that Ivermectin treatment may be linked to lower death rate and better clinical outcomes with a low incidence of adverse effects**.** The inherent methodological limitations and risk of bias conferred variable evidence grading in the findings in various patient outcomes.

Mortality

Several systematic review and meta-analysis were performed to investigate the efficacy of ivermectin for the treatment and prevention of COVID-19, with mixed results in meta-analyses and conclusions. Meta-analyses done by Padhy et al [98] (studies N=3), Hill et al[99] (studies N=6) (**retracted**[100]), Lawrie et al[101] (studies N=5), Nardelli et al[102] (studies N=7), Kow et al[103] (studies N=6), Bryant et al[104] (studies N=13), Kory et al[105] (studies N=10), Hariyanto et al[106] (studies N=8) and the BIRD group[107] (studies N=13) found Ivermectin to be conclusively linked to lower mortality when compared to usual treatment. A network meta-analysis[108] (studies N=2) reported that Ivermectin was linked to lower mortality with a very close statistical significance. Casteneda-Sabogal et al's meta-analysis[109] (studies N=6) and Roman et al[110] (studies N=5) found no conclusive association of Ivermectin with reduced mortality. Of note, the above three studies[108-110] reported low or very low certainty of evidence. However, most of the above analyses have included the retracted study by Elgazzar et al[48]. Recently published Cochrane's review[111] of highly selected low-risk bias studies aimed at evaluating the true-effect of Ivermectin in COVID-19. They expressed uncertainty regarding the effect of Ivermectin on COVID-19 mortality based on 2 outpatient and 2 inpatient RCTs[111]. Our sample size exceeds (studies N=29) that of all the aforementioned studies. We observed mortality overall (N=29) and in the clinical trials subgroup (N=18) meta-analysis. However, no mortality benefit was observed in therapeutic RCTs (mild-moderate N=12, severe/critical N=6), inpatient RCTs (mild-moderate N=5, severe/critical N=6) and observational studies (overall N=11, Inpatient N=8). Using the selection criteria used in Cochrane's meta-analysis, we did not observe a mortality benefit when we limit the analysis for Ivermectin monotherapy in comparison to standard of care or placebo[111]. We would like to emphasize the fact that the observed mortality benefit in some

analyses was frequently seen when Ivermectin was used in combination therapy especially with vitamins, trace elements, other antimicrobials, and steroids. Beneficial effect of steroids has been already been established, which was frequently used as part of standard of care[112]. As we know proper nutrition and activation of the immune system are two crucial elements in fighting the COVID-19 infection[113] therefore it is possible that supplemental vitamins and minerals may help in COVID-19 infection. However, clinical evidence does not currently support routine use of any of these agents for the prevention or treatment of COVID-19, unless a patient has a confirmed or suspected micronutrient deficiency[114]. We speculate that the observed mortality benefit of Ivermectin was influenced by the use of these supplements, either through prescription or patient's own decision for over the counter use.

Our pooled analysis resulting in a low mortality rate of 3.6% with use of Ivermectin, mostly as an adjuvant therapy, is suggestive of its positive impact in lowering mortality in COVID-19 patients. For a valid comparison, it is important to factor in the time window during which the individual studies were conducted. Most studies recorded their data in the II&III quarter of 2020 when mortality rates with various treatments were often higher in respective countries[115]. For instance, the mortality benefit with Ivermectin has been observed on a magnified basis in a population study of 25 Peruvian states. The analysis of this mass administration data revealed a 14 fold drop in deaths a couple months after starting of large-scale Ivermectin use and a 13 fold increase since limiting its use following change in Peru's political scenario[116].

Need for ICU admission and Mechanical Ventilation

Due to the small number of studies and their small individual sample size, benefit with Ivermectin in reducing ICU admissions or mechanical ventilation cannot be concluded with

confidence. In our pooled analysis, we observed significantly lower rates for ICU admission (5.4%) and mechanical ventilation (3.9%) in Ivermectin-treated patients, mostly as an adjuvant therapy, when compared to other treatments[117-119]. It must be noted that our pooled analysis mostly included mild/moderate patients, which may skew the results in favor of Ivermectin.

Adverse events

Our analysis for adverse events was inconclusive. We noticed that most adverse events were non-serious: nausea, vomiting, abdominal pain, diarrhea, pruritus, lethargy, vertigo, tingling, numbness, anxiety, mild hyperglycemia etc. Yet, very few patients reported serious events like organizing pneumonia, hyponatremia, erosive esophagitis, infections/infestations. Erosive esophagitis can be attributed to concomitant use of Doxycycline[120]; hyponatremia[80] was likely from SIADH-a rare COVID-19 complication[121]. Only Lopez-Medina et al[81] (Ivermectin dose = 1500ug/Kg over 5 days) and Mahmud et al[45,122] (Ivermectin dose =12mg twice daily for 5 days) reported drug discontinuation due to adverse-reactions. Given the non-serious nature of most adverse-reactions, and a low pooled rate of 6.6% in comparison to other available treatments[23,123,124], we suggest that Ivermectin was generally well tolerated.

Viral Clearance and time to achieve Viral Clearance

We observed that patients who received Ivermectin in combination with other drugs were far more likely to test negative for RT-PCR as compared to the control group. Hariyanto et al's meta-analysis[106] (N=9) supports our findings. Contrary to our results, Roman et al[110] (N=4) and Cochrane's review[111] found no such difference.

Similarly, when used in combination therapy, Ivermectin appeared to have significantly shortened the time to achieve viral clearance when compared to the non-Ivermectin arm. This finding was also observed in the analysis of Lawrie et al[101] (N=2), Hariyanto et al[106] (N=6) and

the BIRD group[107] (N=4), however, Lawrie et al's[101] results were not statistically significant. It must be noted that these outcomes are subject to technical variations because of the different laboratory parameters as well as the day at which viral clearance was measured.

Need for hospitalization and duration of hospital stay

Our analysis suggests that Ivermectin treatment may help reduce the need for hospitalization. Another study by the BIRD group[107] (N=2) also found this association, yet their analysis did not reach statistical significance.

In our analysis, we found trends of shorter duration of hospital stay but our results were not conclusive, hence more data is needed to confirm this finding. Three other studies[101,106,107] also found similar benefit, only one[107] was not statistically significant. While Roman et al[110] observed that Ivermectin was associated with a longer hospital stay; but without statistical significance. Recently, Cochrane's review[111] also did not find an association between Ivermectin and duration of hospitalization. We must acknowledge the high variation in clinical decision making as well as the availability of resources with respect to hospitalization outcomes.

Our analysis for the true effect of Ivermectin is inconclusive, which supports the conclusion of Cochrane's review[111] that Ivermectin may or may not be effective by itself. COVID-19, being a complex, multi-stage, and multi-system disease, requires a multi-pronged approach. Hazan et al[97] enumerated several microbial diseases currently being successfully treated by a combination of multiple drugs with different individual mechanisms of actions. They highlighted another benefit of multidrug therapy: to avert cases of drug-resistance such as those occurring with Ivermectin-monotherapy against parasitic infections. This is crucial since the newly emerging SARS-CoV2 strains have perpetuated the pandemic in spite of desperate measures taken world-wide. Also, this approach may address concerns regarding the adverse

effects associated with high dose of Ivermectin. Because, drug combinations can possibly boost drug potency such as with the combination used by Hazan et al[97], thus rendering moderate doses to be more effective. Therefore, it is imperative that we thoroughly explore Ivermectin as a part of a multidrug regimen.

On the starting point of the COVID-19 disease spectrum is the acute infectious phase that lasts for up to 2 weeks and is characterized by viral replication[125]. This is followed by the hyper-inflammatory state marked by rise in inflammatory markers[125]. Those surviving this phase may experience long-term multi-organ sequelae for up to six months or even a year[126,127]. Patients progressing to the severe stage require hospitalization and mortality rates among hospitalized COVID-19 patients can be as high as 25%[128]. Dwindling economies, overburdened healthcare systems and the consequent dearth of resources further worsen the prognosis of hospitalized patients, especially in low-income countries. Once progressed to the critical stage, mortality rate of around 50% has been recorded[129]. The management of severe and critical patients mainly consists of supportive treatment for complications of severe COVID-19[130]. The available evidence of the efficacy and safety of the recommended drugs for severe and critical COVID-19 patients is not promising[131-134]. Even before the pandemic, much emphasis has been laid on the importance of preventive and early treatment strategies for ARDS and sepsis to achieve a higher survival rate in patients[135-138]. Drawing upon these recommendations, we hypothesize that employing Ivermectin as an adjuvant therapy for early treatment of COVID-19 cases may allow the body to mount an adequate and well-regulated immune response, thus leading to better outcomes. Considering the bleak prognosis of COVID-19 at the advanced stage, we postulate that we may potentially improve patient outcomes by actively arresting its progression to severe stages with effective and safe early adjuvant treatments like Ivermectin. Finally, we suggest that

understanding the course of this disease- both pathophysiological and symptomatic, and leveraging it is key to achieving the best outcomes at both-patient and population level.

Strengths

To our knowledge, this is the largest patient sample size for a systematic review and meta-analysis on the use of Ivermectin for COVID-19. This study integrates data of approximately 17,000 patients from 52 studies- both trials and observational, conducted globally. Additionally, we obtained robust evidence by conducting various subgroup analyses. One noteworthy Ivermectin study, a large clinical trial[48], was recently withdrawn on grounds of ethical misconduct. Its strongly positive findings accounted for significant effect size in the meta-analyses published so far. This has led us to question the existing conclusions regarding the efficacy of this drug. Ours would be the first meta-analysis that excluded the flawed study to clear the air regarding the effect of Ivermectin in COVID-19 for a stronger empirical evidence of Ivermectin's efficacy. We also excluded studies which did not meet the rigor of true RCTs in the ' RCTs' subgroup. We used GRADE-pro tool[55] to rate certainty of evidence for all outcomes, which was not done in past to provide more insight. The GRADE framework is known to be the most widely used assessment to rate quality of evidence[55]. Sensitivity analyses were performed with the aim of testing the robustness of results. Moreover, we performed pooled analyses to incorporate data from uncontrolled studies.

Limitations

Our results are to be interpreted carefully bearing in mind that we included several non-peer-reviewed articles to obtain the latest data. We cannot preclude the possibility of unreported biases and confounders that could have been recognized by a peer-review process. Furthermore, there was significant heterogeneity in treatment protocols used for dosage, duration, route of

administration in interventional and control group. Our analyses may not have accounted for confounding by concomitant therapy. We only analyzed the mortality outcome as per Cochrane's strict selection criteria for Ivermectin monotherapy compared to standard of care/placebo. Patient demographics and outcome measures varied among different studies. Few studies documented the inclusion of patients <18 years of age. However, the mean/median and dispersion values consistently suggested a predominantly adult population. The clinical classification for severity was inconsistent across the included studies. Most studies were conducted on patients with mild /moderate presentation, which limits the generalizability of our results.

Apart from this, there was insufficient data regarding the time of treatment in the course of the disease, hence inferences could not be made in that regard. We could not confirm adequate control-matching in some observational studies. We advise discretion in interpretation of our results for adverse-event rate since most of the reported adverse-effects could not be measured objectively by investigators. Because most of the studies were conducted in developing nations, not everyone underwent RT-PCR testing owing to limited resources; clinical diagnosis was used instead. Even though RT-PCR is the gold standard for diagnosis, it is subject to its limitations. By virtue of its design, we postulate that this meta-analysis formulated with a random-effects model may have addressed some of the heterogeneity stemming from the above factors. Lastly, we must acknowledge the subjective nature of the GRADE tool used to evaluate the level of evidence[55].

Current status of Ivermectin

In February 2021, the NIH declared that it neither recommends for or against using Ivermectin for COVID-19[139] due to inadequate data. For further guidance, they require evidence from larger, well-designed and well-executed trials. As of March 5,2021, the FDA has warned

people against using Ivermectin for COVID-19[140], specifically against self-medicating with veterinary Ivermectin formulations[140,141]. They are yet to review the evidence but have initiated a preliminary research. In late March, the EMA (European Medicines Agency) stated that Ivermectin cannot be recommended for the prevention or treatment of COVID-19 outside clinical trials[142]. Similarly, the WHO suggested limiting Ivermectin use to clinical trials until more data is available[143]. A large phase 3 clinical trial evaluating the use of Ivermectin in COVID-19 patients with mild to moderate symptoms is yet to be concluded[144]. The NIH, FDA ,CDC, EMA and several other important government and private sector bodies will collaborate on this "Master protocol" titled ACTIV-6 that focuses on rigorous testing of up to seven repurposed drugs[145]. Recently, the CDC issued warning against the use of non-prescription Ivermectin as well as the ingestion of Ivermectin-containing topical or veterinary products and advised seeking immediate medical care for any adverse effects arising out of such events[146].

Conclusion

In summary, based on updated evidence, benefit of Ivermectin as monotherapy or in combination treatment for lowering the COVID-19 associated mortality is inconclusive due to lack of high-quality RCTs. Ivermectin combination therapy may play a role in controlling the viral replication and preventing the need for hospitalization. Using well-designed larger observational studies[147,148] and clinical trials, we need to further investigate its efficacy, its ideal dosage and timing in the disease course, drug interactions and possible synergistic drug combinations to achieve maximum benefit. We also need to evaluate the benefit of Ivermectin for treating the various emerging strains as well as its role in vaccinated individuals. We propose pragmatic practice embedded platform trials[149] to test this and other re-purposed and novel therapies specifically in severe COVID-19 patients and other critically ill patients. We

recommend the medical practitioners to exercise caution until further evidence is available and use their best clinical judgement while prescribing Ivermectin in COVID-19 patients.

References:

1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed.* 2020;91(1):157-160.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.* 2020;20(5):533-534.
3. Domecq JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry. *Critical Care Medicine.* 9000;Online First.
4. Bansal V, Singh R, Bhurwal A, Rathore S, Kashyap R. 117: Obesity Is a Risk Factor for Increased COVID-19 Severity: A Systemic Review and Meta-Regression. *Critical Care Medicine.*49(1):43.
5. Menon T, Gandhi SAQ, Tariq W, et al. Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis. *Cureus.* 2021;13(4):e14279.
6. Menon T, Sharma R, Kataria S, et al. The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. *Cureus.* 2021;13(3):e13894.
7. Singh R, Shiza ST, Saadat R, Dawe M, Rehman U. Association of Guillain-Barre Syndrome With COVID-19: A Case Report and Literature Review. *Cureus.* 2021;13(3):e13828.
8. Menon T, Sharma R, Earthineni G, et al. Association of Gastrointestinal System With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis. *Cureus.* 2021;13(2):e13317.
9. Razonable RR, Pennington KM, Meehan AM, et al. A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting. *Mayo Clinic Proceedings.* 2020;95(7):1467-1481.
10. Rathore SS, Rojas GA, Sondhi M, et al. *Myocarditis associated with Covid-19 disease: a systematic review of published Case reports and Case series.* Preprints; 2021/02/01/ 2021.
11. Sheraton M, Deo N, Kashyap R, Surani S. A Review of Neurological Complications of COVID-19. *Cureus.* 2020;12(5):e8192.
12. Khan H, Sabzposh H, Deshpande S, Kashyap R. Pregnancy during COVID-19 pandemic - Maternal and neonatal outcomes: A concise review. *International Journal of Academic Medicine.* 2020;6(4):287-293.
13. Shah K, Mann S, Singh R, Bangar R, Kulkarni R. Impact of COVID-19 on the Mental Health of Children and Adolescents. *Cureus.* 2020;12(8):e10051.
14. Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of the COVID 19 pandemic on healthcare workers globally: A systematic review. *Psychiatry Res.* 2020;292:113360.
15. Singh R, Kashyap R, Hutton A, Sharma M, Surani S. A Review of Cardiac Complications in Coronavirus Disease 2019. *Cureus.* 2020;12(5):e8034.
16. Bhalala U, Gist K, Tripathi S, et al. 145: Pediatric COVID-19: A Report From Viral Infection and Respiratory Illness Universal Study (VIRUS). *Critical Care Medicine.*49(1):58.
17. Tripathi S, Gist K, Chiotos K, et al. 61: Risk Factors for Severe COVID-19 Illness in Children: Analysis of the VIRUS: COVID-19 Registry. *Critical Care Medicine.*49(1):32.
18. Md Insiat Islam R. Current Drugs with Potential for Treatment of COVID-19: A Literature Review. *J Pharm Pharm Sci.* 2020;23(1):58-64.

19. Gilzad-Kohan H, Jamali F. Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2. *J Pharm Pharm Sci.* 2020;23:259-277.
20. Bansal V, Mahapure KS, Mehra I, et al. Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis. *Front Med (Lausanne).* 2021;8:624924.
21. Singh R, Rathore SS, Khan H, et al. Mortality and Severity in COVID-19 Patients on ACEIs & ARBs-A Meta-Regression Analysis. *medRxiv.* 2021.
22. Mahmud S, Nagraj S, Karia R, et al. 140: Efficacy and Safety of Tocilizumab in Hospitalized COVID-19 Patients: A Systematic Review. *Critical Care Medicine.* 2021;49(1):55.
23. Bansal V, Mahapure KS, Bhurwal A, et al. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. *Front Med (Lausanne).* 2020;7:606429.
24. Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. *J Antibiot (Tokyo).* 2017;70(5):495-505.
25. Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. *Ann Clin Microbiol Antimicrob.* 2020;19(1):23.
26. Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. *Antiviral Res.* 2013;100(3):662-672.
27. Tay MY, Fraser JE, Chan WK, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. *Antiviral Res.* 2013;99(3):301-306.
28. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochem J.* 2012;443(3):851-856.
29. DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. *Open Heart.* 2020;7(2).
30. Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. *Inflamm Res.* 2008;57(11):524-529.
31. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 2020;178:104787.
32. Gorial FI, Mashhadani S, Sayaly HM, et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). *medRxiv.* 2020.
33. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. *Chest.* 2021;159(1):85-92.
34. Bhattacharya R, Ray I, Mukherjee R, Chowdhury S, Kulasreshtha M, Ghosh R. Observational Study on Clinical Features, Treatment and Outcome of Covid 19 in a Tertiary Care Centre in India - a Retrospective Case Series. *International Journal of Scientific Research.* 2020;9(10):1-3.
35. Chowdhury AMM, Shahbaz M, Karim MR, Islam J, Dan G, He SX. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients. *Eurasian Journal of Medicine and Oncology.* 2021;5(1):63-70.
36. Mega ER. Latin America's embrace of an unproven COVID treatment is hindering drug trials. *Nature.* 2020;586(7830):481-482.
37. Trial Site Staff. Beyond The Roundup | First EU Nation To Approve Ivermectin For Covid-19. https://trialsitenews.com/beyond-the-roundup-first-eu-nation-to-approve-ivermectin-for-covid-19/. Published January 30, 2021. Accessed 02.14.2021.

38. Nayar S, Khanna P, Anand P, et al. Ivermectin in Covid-19: Review of the Current Evidence. *The Indian Practitioner.* 2021;74(3):27-33.
39. AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group (Dte.GHS). CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID-19 PATIENTS. Ministry of Health & Family Welfare, Government of India. https://www.mohfw.gov.in/pdf/COVID19ManagementAlgorithm22042021v1.pdf. Published 2021. Updated 04/22/2021. Accessed 04/25/2021.
40. Chamie-Quintero JJ, Hibberd J, Scheim D. Sharp reductions in COVID-19 case fatalities and excess deaths in Peru in close time conjunction, state-by-state, with ivermectin treatments. *State-By-State, with Ivermectin Treatments (January 12, 2021).* 2021.
41. Yagisawa M, Foster PJ, Hanaki H, Ōmura S. Global trends in clinical studies of ivermectin in COVID-19. *THE JAPANESE JOURNAL OF ANTIBIOTICS.* 2021;74:1.
42. Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients. *medRxiv.* 2020.
43. Lima-Morales R, Mendez-Hernandez P, Flores YN, et al. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. *Int J Infect Dis.* 2021;105:598-605.
44. Niaee MS, Gheibi N, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. *Research Square.* 2020.
45. Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. *J Int Med Res.* 2021;49(5):3000605211013550.
46. Ravindra G, Chitra L, Madhur M, et al. Retrospective Assessment of Treatments of Hospitalized Covid-19 Patients. *medRxiv.* 2021.
47. Samaha AA, Mouawia H, Fawaz M, et al. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. *Viruses.* 2021;13(6).
48. Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. *Research Square.* 2020.
49. The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4 for Windows. Oxford, England: The Cochrane Collaboration. https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download. Published 2020. Accessed 01/31/2021.
50. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta-analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021.
51. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of interventions.* John Wiley & Sons; 2019.
52. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
53. Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. *Jama.* 2002;287(22):2973-2982.
54. National Heart L, and Blood Institute,. Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Updated 04/14/2021. Accessed 04/14/2021, 2020.

55. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. *Updated October.* 2013;2013.
56. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. *Available at SSRN 3734478.* 2020.
57. Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. *Int J Infect Dis.* 2021;103(Feb):214-216.
58. Ahsan T, Rani B, Siddiqui R, et al. Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan. *Cureus.* 2021;13(4):e14761.
59. Robin RC, Alam RF, Saber S, Bhiuyan E, Murshed R, Alam MT. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. *Journal of Bangladesh College of Physicians and Surgeons.* 2020;38(0):10-15.
60. Babalola OE, Bode CO, Ajayi AA, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. *QJM.* 2021.
61. Biber A, Mandelboim M, Harmelin G, et al. Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. *medRxiv.* 2021.
62. Budhiraja S, Soni A, Jha V, et al. Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience. *medRxiv.* 2020.
63. Shah Bukhari KH, Asghar A, Perveen N, et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease. *medRxiv.* 2021.
64. Camprubi D, Almuedo-Riera A, Marti-Soler H, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. *PLoS One.* 2020;15(11):e0242184.
65. Carvallo H. Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19 - Study Results - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/results/NCT04425863?view=results. Published 2020. Updated 10/19/2020. Accessed 02/12/2021.
66. Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. *EClinicalMedicine.* 2021;32(100720):100720.
67. Zeeshan Khan Chachar A, Ahmad Khan K, Asif M, Tanveer K, Khaqan A, Basri R. Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. *International Journal of Sciences.* 2020;9(09):31-35.
68. Chahla RE, Ruiz LM, Mena T, et al. Cluster Randomised Trials-Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers. *Research Square.* 2021.
69. Elalfy H, Besheer T, El-Mesery A, et al. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. *J Med Virol.* 2021;93(5):3176-3183.
70. Espitia-Hernandez G, Munguia L, Diaz-Chiguer D, López-Elizalde R, Jimenez-Ponce F. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. *Biomedical Research.* 2020;31(5):129-133.
71. Galan LEB, Santos NMD, Asato MS, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. *Pathog Glob Health.* 2021;115(4):235-242.

72. Gonzalez JLB, González Gámez M, Enciso EAM, et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial. *medRxiv.* 2021.
73. Guzmán MJM, Castillo-Gonzalez A, Gonzalez JLB, et al. Factors associated with increased mortality in critically ill COVID-19 patients in a Mexican public hospital: the other faces of health system oversaturation. *medRxiv.* 2021.
74. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. *medRxiv.* 2020:2020.2010.2026.20219345.
75. Hussain SMA, Shuayb M, Rahman M. Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh. *International Journal of Molecular & Immuno Oncology.* 2021;6(1):27-29.
76. Release HP. Kovid-19 - Huvemek® Phase 2 clinical trial -. Huvepharma https://huvemec.bg/covid-19-huvemec-klinichno-izpitanie/za-isledvaneto/. Updated 03/25/2021. Accessed 05/22/2021.
77. Khan MSI, Khan MSI, Debnath CR, et al. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. *Arch Bronconeumol (Engl Ed).* 2020;56(12):828-830.
78. Ravikirti, Roy R, Pattadar C, et al. Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial. *medRxiv.* 2021.
79. Kishoria N, Mathur SL, Parmar V, et al. IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY. *Paripex Indian Journal of Research.* 2020;9(8):1-4.
80. Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. *EClinicalMedicine.* 2021;37.
81. Lopez-Medina E, Lopez P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. *Jama.* 2021;325(14):1426-1435.
82. Pierre L, Christine F. Ivermectin and COVID-19 in Care Home: Case Report. *Journal of Infectious Diseases and Epidemiology.* 2021;7(4):1-4.
83. Mohan A, Tiwari P, Suri T, et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial. *Research Square.* 2021.
84. Morgenstern J, Redondo JN, De León A, et al. The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020. *J Clin Trials.* 2020;11(S9:1000002):1-4.
85. Mourya S, Thakur AS, Hada DS, Kulshreshtha VS, Sharma Y. Comparative Analytical Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in Index Medical College Hospital and Research Center, Indore, India. *International Journal of Health and Clinical Research.* 2021;4(6):265-267.
86. Núñez AC, Yuca GG, Cervantes JML, Murcia APR, Juárez MAO, Martínez JJ. Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with COVID-19 Study conducted at the Social Security Institute for Workers of the State of Chiapas, ISSTECH, Mexico. *International Journal of Innovative Science and Research Technology.* 2020;5(7):211-215.
87. Podder CS, Chowdhury N, Sina MI, Haque WMMU. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. *IMC Journal of Medical Science.* 2020;14(2:002):11-18.

88. Okumus N, Demirturk N, Cetinkaya RA, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. *BMC Infect Dis.* 2021;21(1):411.
89. Pott-Junior H, Bastos Paoliello MM, Miguel AQC, et al. Use of ivermectin in the treatment of Covid-19: A pilot trial. *Toxicol Rep.* 2021;8(0):505-510.
90. Rahman MA, Iqbal SA, Islam MA, Niaz MK, Hussain T, Siddiquee TH. Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients. *Journal of Bangladesh College of Physicians and Surgeons.* 2020;38:5-9.
91. Shahbaznejad L, Davoudi A, Eslami G, et al. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial. *Clin Ther.* 2021.
92. Soto-Becerra P, Culquichicón C, Hurtado-Roca Y, Araujo-Castillo RV. Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru. *medRxiv.* 2020.
93. Spoorthi V, Sasank S. Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV2. *IAIM.* 2020;7(10):177-182.
94. Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. *J Med Virol.* 2021;93(10):5833-5838.
95. Aref ZF, Bazeed S, Hassan MH, et al. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19. *Int J Nanomedicine.* 2021;16:4063-4072.
96. Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. *BMC Infect Dis.* 2021;21(1):635.
97. Hazan S, Dave S, Gunaratne AW, et al. Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients. *medRxiv.* 2021.
98. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. *J Pharm Pharm Sci.* 2020;23:462-469.
99. Hill A, Abdulamir A, Ahmed S, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. *Research Square.* 2021.
100. Hill A, Garratt A, Levi J, et al. Erratum: Expression of Concern: "Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection". *Open Forum Infect Dis.* 2021;8(8):ofab394.
101. Lawrie T. *Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. (Latest version v1.2 - 6 Jan 2021).* 2021.
102. Nardelli P, Zangrillo A, Sanchini G, et al. Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use? *Signa Vitae.* 2021;1:2.
103. Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. *Pharmacol Rep.* 2021:1-7.
104. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. *Am J Ther.* 2021.

105. Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. *American Journal of Therapeutics.* 2021;28(3):e299-e318.
106. Hariyanto TI, Halim DA, Rosalind J, Gunawan C, Kurniawan A. Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies. *Reviews in Medical Virology.* 2021;e2265:1-15.
107. British Ivermectin Recommendation Development. The BIRD Recommendation on the Use of Ivermectin for Covid-19. https://www.francesoir.fr/sites/francesoir/files/media-icons/bird-proceedings-02-03-2021-v151.pdf. Published 2021. Accessed 04.01.2021.
108. Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. *PLoS Med.* 2020;17(12):e1003501.
109. Castañeda-Sabogal A, Chambergo-Michilot D, Toro-Huamanchumo CJ, Silva-Rengifo C, Gonzales-Zamora J, Barboza JJ. Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis. *medRxiv.* 2021:2021.2001.2026.21250420.
110. Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. *medRxiv.* 2021.
111. Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. *Cochrane Database Syst Rev.* 2021;7(7):CD015017.
112. NIH. Corticosteroids | COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/. Published 2021. Updated 08/04/2021. Accessed 08/25/2021.
113. Derbyshire E, Delange J. COVID-19: is there a role for immunonutrition, particularly in the over 65s? *BMJ Nutr Prev Health.* 2020;3(1):100-105.
114. Bauer SR, Kapoor A, Rath M, Thomas SA. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? *Cleve Clin J Med.* 2020.
115. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. WHO. https://covid19.who.int/. Updated 02.14.2021. Accessed 02.14.2021.
116. Chamie-Quintero J, Hibberd JA, Scheim D. Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=. 002 for effect by state, then 13-fold increase after ivermectin use restricted. 2021.
117. Abate SM, Ahmed Ali S, Mantfardo B, Basu B. Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis. *PLoS One.* 2020;15(7):e0235653.
118. Elsayed HH, Hassaballa AS, Ahmed TA, Gumaa M, Sharkawy HY. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: a systematic review and meta-analysis. 2020.
119. Richardson S. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area (published online ahead of print, 2020 Apr 22). *Jama.*
120. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. *Drug Saf.* 2000;22(3):237-249.
121. Yousaf Z, Al-Shokri SD, Al-Soub H, Mohamed MFH. COVID-19-associated SIADH: a clue in the times of pandemic! *Am J Physiol Endocrinol Metab.* 2020;318(6):E882-E885.
122. Mahmud R. Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection. Dhaka Medical College Bangladesh. https://clinicaltrials.gov/ct2/show/study/NCT04523831. Published 2020. Updated October 9, 2020. Accessed 02.14.2021.

123. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med.* 2020;383(19):1813-1826.
124. Group WHOREAfC-TW, Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *Jama.* 2020;324(13):1330-1341.
125. Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. *Jama.* 2020;324(22):2251-2252.
126. Boscolo-Rizzo P, Guida F, Polesel J, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). *Int Forum Allergy Rhinol.* 2021.
127. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med.* 2021;27(4):601-615.
128. Gunster C, Busse R, Spoden M, et al. 6-month mortality and readmissions of hospitalized COVID-19 patients: A nationwide cohort study of 8,679 patients in Germany. *PLoS One.* 2021;16(8):e0255427.
129. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *Jama.* 2020;323(13):1239-1242.
130. CDC. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). Centers for Disease Control Prevention. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Published 2020. Updated 02/12/2021. Accessed 06/19/2021.
131. Group RC. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. *Lancet.* 2021;397(10289):2049-2059.
132. Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. *Jama.* 2021;325(12):1185-1195.
133. Garibaldi BT, Wang K, Robinson ML, et al. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. *JAMA Netw Open.* 2021;4(3):e213071.
134. Bayram N, Ozsaygili C, Sav H, et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. *Jpn J Ophthalmol.* 2021;65(4):515-525.
135. Festic E, Kor DJ, Gajic O. Prevention of acute respiratory distress syndrome. *Curr Opin Crit Care.* 2015;21(1):82-90.
136. Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. *Am J Respir Crit Care Med.* 2011;183(4):462-470.
137. Lat I, Coopersmith CM, De Backer D, et al. The Surviving Sepsis Campaign: Fluid Resuscitation and Vasopressor Therapy Research Priorities in Adult Patients. *Crit Care Med.* 2021;49(4):623-635.
138. Youkee D, Hulme W, Roberts T, Daniels R, Nutbeam T, Keep J. Time Matters: Antibiotic Timing in Sepsis and Septic Shock. *Crit Care Med.* 2016;44(10):e1016-1017.
139. National Institutes of Health. Ivermectin | COVID-19 Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ivermectin/. Published 2020. Updated February 11, 2021. Accessed 02.14.2021.
140. FDA. FAQ: COVID-19 and Ivermectin Intended for Animals | FDA. FDA. https://www.fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-

ivermectin-intended-animals. Published 2020. Updated 12/16/2020. Accessed 02.14.2021.

141. FDA. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19 | FDA. https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19. Published 2021. Updated 03.05.2021. Accessed 04.10.2021.

142. European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials | European Medicines Agency. https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials. Published 2021. Updated 03.22.2021. Accessed 04.10.2021.

143. World Health Organization. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published 2021. Updated 03/31/2021. Accessed 08/25/2021.

144. ACTIV-6: COVID-19 Study of Repurposed Medications. https://clinicaltrials.gov/ct2/show/NCT04885530. Published 2021. Updated 08/30/2021. Accessed 09/02/2021.

145. National Institutes of Health. NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options. https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options. Updated 04/17/2020. Accessed 08/25/2021.

146. CDC Health Alert Network. CDCHAN-00449: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19. https://emergency.cdc.gov/han/2021/han00449.asp?ACSTrackingID=USCDC_511-DM64535&ACSTrackingLabel=HAN%20449%20-%20General%20Public&deliveryName=USCDC_511-DM64535. Published 2021. Updated 08/26/2021. Accessed 09/03/2021.

147. Walkey AJ, Sheldrick RC, Kashyap R, et al. Guiding Principles for the Conduct of Observational Critical Care Research for Coronavirus Disease 2019 Pandemics and Beyond: The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study Registry. *Crit Care Med.* 2020;48(11):e1038-e1044.

148. Walkey AJ, Kumar VK, Harhay MO, et al. The Viral Infection and Respiratory Illness Universal Study (VIRUS): An International Registry of Coronavirus 2019-Related Critical Illness. *Crit Care Explor.* 2020;2(4):e0113.

149. FDA. FDA experts discuss COVID-19 therapeutic clinical trials | American Medical Association. AMA Webinar Series. https://www.ama-assn.org/delivering-care/public-health/fda-experts-discuss-covid-19-therapeutic-clinical-trials. Updated 03/17/2021. Accessed 04/15/2021.

Figure and Table Legends:

Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow—study inclusion. ICU: Intensive Care Unit, CDC: Centers for Disease Control and Prevention, RCT: Randomized controlled trial, WHO: World Health Organization

Figure 2: Meta-analysis for Ivermectin use and overall Mortality

Figure 3: Subgroup analysis for Ivermectin use and mortality by study design and hospitalized patients

Figure 4 Effect of Ivermectin Monotherapy compared with Placebo/Standard of Care in RCTs as per Cochrane's criteria

Figure 5: Meta-analysis for Ivermectin use and need for ICU admission, mechanical ventilation and Adverse events

Figure 6: Meta-analysis for Ivermectin use and need for Viral Clearance, Time to achieve viral clearance, Need for hospitalization and Duration of hospital stay

e-figure 1 Sensitivity analysis excluding Lima-morales et al: Mortality in Clinical trials

e-figure 2 Sensitivity analysis excluding Vallejos et al: Mortality in Therapeutic RCTs: Mild-Moderate COVID-19

e-figure 3 Sensitivity analysis excluding Soto-Becerra et al: Mortality in observational studies

e-figure 4 Sensitivity analysis excluding Soto-Becerra et al: Mortality in hospitalized patients-Overall

e-figure 5 Sensitivity analysis excluding Abd-elsalam et al: Mortality in hospitalized patients by study design RCTs: Mild-Moderate COVID-19

e-figure 6 Sensitivity Analysis excluding Soto-Becerra et al: Mortality in inpatient observational studies

e-figure 7 Pooled Analysis for Mortality

e-figure 8 Pooled analysis of need for ICU admission

e-figure 9 Pooled analysis of Mechanical Ventilation

e-figure 10 Pooled Analysis of Adverse events

e-figure 11 Sensitivity Analysis excluding Maurya et al : Viral Clearance

e-figure 12 Sensitivity Analysis excluding Khan et al : Time to achieve Viral Clearance

e-figure 13 Sensitivity Analysis excluding Mahmud et al : Need for hospitalization

e-figure 14 Sensitivity Analysis excluding Gonzalez et al : Duration of hospital stay

e-figure 15 Funnel Plot overall mortality

e-figure 16 Funnel Plot Mortality in Clinical Trials

e-figure 17 Funnel Plot Mortality in RCTs: Mild/Moderate COVID-19

e-figure 18 Funnel Plot Mortality in RCTs: Severe/Critical COVID-19

e-figure 19 Funnel Plot Mortality in Observational studies

e-figure 20 Funnel Plot Mortality in Hospitalized patient overall

e-figure 21 Funnel Plot Mortality in Inpatient RCTs: Mild-Moderate COVID-19

e-figure 22 Funnel Plot Mortality in Inpatient RCTs: Severe/Critical COVID-19

e-figure 23 Funnel Plot Mortality in Inpatient Observational studies

e-figure 24 Funnel Plot for Mortality with Ivermectin Monotherapy as per Cochrane's Criteria

e-figure 25 Funnel Plot Need for ICU Admission

e-figure 26 Funnel Plot Need for Mechanical Ventilation

e-figure 27 Funnel Plot Adverse event

e-figure 28 Funnel Plot Need for Hospitalization

e-figure 29 Funnel Plot duration of Hospital stay

e-figure 30 Funnel Plot Incidence of Viral Clearance

e-figure 31 Funnel Plot Time to achieve viral clearance

e-table 1. Study characteristic table for all included studies

e-table 2. Cochrane Risk of bias assessment of the trials included in the study

e-table 3. Correlation of quality measures with estimates of treatment effects assessment of the trials those were included in the study

e-table 4. NIH quality assessment Tool for case series included in the study

e-table 5. NIH Quality Assessment of Case-Control Studies

e-table 6. NIH Quality Assessment of Observational Cohort and Cross-Sectional Studies

e-table 7. Certainty of the evidence (GRADE) Profile at Outcome Level

e-table 8. Ongoing clinical trials

Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow—study inclusion. ICU: Intensive Care Unit, CDC: Centers for Disease Control and Prevention, RCT: Randomized controlled trial, WHO: World Health Organization



Figure 2: Meta-analysis for Ivermectin use and overall Mortality

Figure 2A: Mortality Overall

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Abd-elsalam et al	3	82	4	82	4.5%	0.74 [0.16, 3.42]
Ahsan et al	17	110	17	55	6.9%	0.41 [0.19, 0.88]
Babalola et al	0	42	0	20		Not estimable
Budhiraja et al	0	34	103	942	2.1%	0.12 [0.01, 1.93]
Cadegiani et al	0	110	2	137	1.8%	0.25 [0.01, 5.16]
Chaccour et al	0	12	0	12		Not estimable
Chahla et al	0	110	0	62		Not estimable
Elalfy et al	0	62	0	51		Not estimable
Galan et al	12	53	25	115	6.9%	1.05 [0.48, 2.30]
Ghooi et al	3	15	77	1020	5.2%	3.06 [0.85, 11.08]
Gonzalez et al	5	36	8	70	5.5%	1.25 [0.38, 4.14]
Gorial et al	0	16	2	71	1.8%	0.84 [0.04, 18.39]
Guzman et al	48	122	39	74	7.5%	0.58 [0.32, 1.04]
Hashim et al	2	70	6	70	4.2%	0.31 [0.06, 1.61]
Khan et al	1	115	9	133	3.2%	0.12 [0.02, 0.97]
Kirti et al	0	55	4	57	1.9%	0.11 [0.01, 2.04]
Lima-Morales et al	13	434	52	287	7.4%	0.14 [0.07, 0.26]
Lopez-Medina et al	0	200	1	198	1.7%	0.33 [0.01, 8.11]
Loué et al	1	10	5	15	2.7%	0.22 [0.02, 2.28]
Mahmud et al	0	183	3	180	1.9%	0.14 [0.01, 2.69]
Mohan et al	0	100	0	52		Not estimable
Mourya et al	0	50	0	50		Not estimable
Niaee et al	4	120	11	60	5.5%	0.15 [0.05, 0.51]
Okumus et al	6	30	9	30	5.5%	0.58 [0.18, 1.91]
Rajter et al	26	173	27	107	7.5%	0.52 [0.29, 0.96]
Shahbaznejad et al	1	35	0	34	1.7%	3.00 [0.12, 76.24]
Soto-Becerra et al	132	561	940	5122	8.4%	1.37 [1.11, 1.68]
Vallejos et al	4	250	3	251	4.5%	1.34 [0.30, 6.07]
Veerapaneni et al	1	50	0	50	1.7%	3.06 [0.12, 76.95]
Total (95% CI)		**3240**		**9407**	**100.0%**	**0.54 [0.34, 0.86]**
Total events	279		1347			

Heterogeneity: Tau² = 0.66; Chi² = 87.53, df = 22 (P < 0.00001); I² = 75%
Test for overall effect: Z = 2.61 (P = 0.009)



Figure 2B Sensitivity analysis Mortality Overall excluding Soto-Becerra et al

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Abd-elsalam et al	3	82	4	82	4.6%	0.74 [0.16, 3.42]
Ahsan et al	17	110	17	55	8.3%	0.41 [0.19, 0.88]
Babalola et al	0	42	0	20		Not estimable
Budhiraja et al	0	34	103	942	1.9%	0.12 [0.01, 1.93]
Cadegiani et al	0	110	2	137	1.6%	0.25 [0.01, 5.16]
Chaccour et al	0	12	0	12		Not estimable
Chahla et al	0	110	0	62		Not estimable
Elalfy et al	0	62	0	51		Not estimable
Galan et al	12	53	25	115	8.3%	1.05 [0.48, 2.30]
Ghooi et al	3	15	77	1020	5.5%	3.06 [0.85, 11.08]
Gonzalez et al	5	36	8	70	6.0%	1.25 [0.38, 4.14]
Gorial et al	0	16	2	71	1.6%	0.84 [0.04, 18.39]
Guzman et al	48	122	39	74	9.4%	0.58 [0.32, 1.04]
Hashim et al	2	70	6	70	4.2%	0.31 [0.06, 1.61]
Khan et al	1	115	9	133	3.0%	0.12 [0.02, 0.97]
Kirti et al	0	55	4	57	1.7%	0.11 [0.01, 2.04]
Lima-Morales et al	13	434	52	287	9.2%	0.14 [0.07, 0.26]
Lopez-Medina et al	0	200	1	198	1.5%	0.33 [0.01, 8.11]
Loué et al	1	10	5	15	2.5%	0.22 [0.02, 2.28]
Mahmud et al	0	183	3	180	1.7%	0.14 [0.01, 2.69]
Mohan et al	0	100	0	52		Not estimable
Mourya et al	0	50	0	50		Not estimable
Niaee et al	4	120	11	60	6.0%	0.15 [0.05, 0.51]
Okumus et al	6	30	9	30	6.0%	0.58 [0.18, 1.91]
Rajter et al	26	173	27	107	9.3%	0.52 [0.29, 0.96]
Shahbaznejad et al	1	35	0	34	1.5%	3.00 [0.12, 76.24]
Soto-Becerra et al	132	561	940	5122	0.0%	1.37 [1.11, 1.68]
Vallejos et al	4	250	3	251	4.6%	1.34 [0.30, 6.07]
Veerapaneni et al	1	50	0	50	1.5%	3.06 [0.12, 76.95]
Total (95% CI)		**2679**		**4285**	**100.0%**	**0.49 [0.32, 0.75]**
Total events	147		407			

Heterogeneity: Tau² = 0.40; Chi² = 43.91, df = 21 (P = 0.002); I² = 52%
Test for overall effect: Z = 3.28 (P = 0.001)



Figure 3: Subgroup analysis for Ivermectin use and mortality by study design and hospitalized patients

Figure 3A Subgroup analysis by study designs- Mortality in Clinical trials

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Abd-elsalam et al	3	82	4	82	8.4%	0.74 [0.16, 3.42]
Babalola et al	0	42	0	20		Not estimable
Chaccour et al	0	12	0	12		Not estimable
Chahla et al	0	110	0	62		Not estimable
Elalfy et al	0	62	0	51		Not estimable
Galan et al	12	53	25	115	13.0%	1.05 [0.48, 2.30]
Gonzalez et al	5	36	8	70	10.3%	1.25 [0.38, 4.14]
Gorial et al	0	16	2	71	3.4%	0.84 [0.04, 18.39]
Hashim et al	2	70	6	70	7.9%	0.31 [0.06, 1.61]
Kirti et al	0	55	4	57	3.7%	0.11 [0.01, 2.04]
Lima-Morales et al	13	434	52	287	13.9%	0.14 [0.07, 0.26]
Lopez-Medina et al	0	200	1	198	3.2%	0.33 [0.01, 8.11]
Mahmud et al	0	183	3	180	3.6%	0.14 [0.01, 2.69]
Mohan et al	0	100	0	52		Not estimable
Niaee et al	4	120	11	60	10.4%	0.15 [0.05, 0.51]
Okumus et al	6	30	9	30	10.4%	0.58 [0.18, 1.91]
Shahbaznejad et al	1	35	0	34	3.2%	3.00 [0.12, 76.24]
Vallejos et al	4	250	3	251	8.5%	1.34 [0.30, 6.07]
Total (95% CI)		**1890**		**1702**	**100.0%**	**0.47 [0.25, 0.90]**
Total events	50		128			

Heterogeneity: Tau² = 0.68; Chi² = 29.34, df = 12 (P = 0.004); I² = 59%
Test for overall effect: Z = 2.27 (P = 0.02)



Figure 3B Subgroup analysis by study designs- Mortality in Therapeutic RCTs: Mild-Moderate COVID-19

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Abd-elsalam et al	3	82	4	82	24.0%	0.74 [0.16, 3.42]
Babalola et al	0	42	0	20		Not estimable
Chaccour et al	0	12	0	12		Not estimable
Chahla et al	0	110	0	62		Not estimable
Hashim et al	0	48	0	48		Not estimable
Kirti et al	0	55	4	57	11.7%	0.11 [0.01, 2.04]
Lopez-Medina et al	0	200	1	198	10.4%	0.33 [0.01, 8.11]
Mahmud et al	0	183	3	180	11.6%	0.14 [0.01, 2.69]
Mohan et al	0	100	0	52		Not estimable
Niaee et al	1	103	10	55	18.0%	0.04 [0.01, 0.36]
Shahbaznejad et al	0	28	0	31		Not estimable
Vallejos et al	4	250	3	251	24.3%	1.34 [0.30, 6.07]
Total (95% CI)		**1213**		**1048**	**100.0%**	**0.31 [0.09, 1.04]**
Total events	8		25			

Heterogeneity: Tau² = 0.97; Chi² = 9.09, df = 5 (P = 0.11); I² = 45%
Test for overall effect: Z = 1.90 (P = 0.06)



Figure 3C Subgroup analysis by study designs- Mortality in Therapeutic RCTs: Severe/Critical COVID-19

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Galan et al	12	53	25	115	45.3%	1.05 [0.48, 2.30]
Gonzalez et al	5	36	8	70	19.3%	1.25 [0.38, 4.14]
Hashim et al	2	22	6	22	9.2%	0.27 [0.05, 1.50]
Niaee et al	3	17	1	5	4.3%	0.86 [0.07, 10.67]
Okumus et al	6	30	9	30	19.6%	0.58 [0.18, 1.91]
Shahbaznejad et al	1	7	0	3	2.3%	1.62 [0.05, 51.11]
Total (95% CI)		**165**		**245**	**100.0%**	**0.86 [0.51, 1.45]**
Total events	29		49			

Heterogeneity: Tau² = 0.00; Chi² = 2.94, df = 5 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.56)



Figure 3D: Subgroup analysis by study designs- Mortality in observational studies

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Ahsan et al	17	110	17	55	15.2%	0.41 [0.19, 0.88]
Budhiraja et al	0	34	103	942	3.7%	0.12 [0.01, 1.93]
Cadegiani et al	0	110	2	137	3.2%	0.25 [0.01, 5.16]
Ghooi et al	3	15	77	1020	10.4%	3.06 [0.85, 11.08]
Guzman et al	48	122	39	74	17.1%	0.58 [0.32, 1.04]
Khan et al	1	115	9	133	5.8%	0.12 [0.02, 0.97]
Loué et al	1	10	5	15	4.9%	0.22 [0.02, 2.28]
Mourya et al	0	50	0	50		Not estimable
Rajter et al	26	173	27	107	16.9%	0.52 [0.29, 0.96]
Soto-Becerra et al	132	561	940	5122	20.0%	1.37 [1.11, 1.68]
Veerapaneni et al	1	50	0	50	2.9%	3.06 [0.12, 76.95]
Total (95% CI)		**1350**		**7705**	**100.0%**	**0.64 [0.35, 1.16]**
Total events	229		1219			

Heterogeneity: Tau² = 0.44; Chi² = 33.58, df = 9 (P = 0.0001); I² = 73%
Test for overall effect: Z = 1.48 (P = 0.14)



Figure 3E: Mortality in hospitalized patients-Overall

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Abd-elsalam et al	3	82	4	82	5.1%	0.74 [0.16, 3.42]
Ahsan et al	17	110	17	55	9.3%	0.41 [0.19, 0.88]
Budhiraja et al	0	34	103	942	2.1%	0.12 [0.01, 1.93]
Galan et al	12	53	25	115	9.2%	1.05 [0.48, 2.30]
Ghooi et al	3	15	77	1020	6.2%	3.06 [0.85, 11.08]
Gonzalez et al	5	36	8	70	6.6%	1.25 [0.38, 4.14]
Gorial et al	0	16	2	71	1.8%	0.84 [0.04, 18.39]
Guzman et al	48	122	39	74	10.6%	0.58 [0.32, 1.04]
Hashim et al	2	22	6	22	4.3%	0.27 [0.05, 1.50]
Khan et al	1	115	9	133	3.3%	0.12 [0.02, 0.97]
Kirti et al	0	55	4	57	1.9%	0.11 [0.01, 2.04]
Mohan et al	0	100	0	52		Not estimable
Niaee et al	4	120	11	60	6.7%	0.15 [0.05, 0.51]
Okumus et al	6	30	9	30	6.7%	0.58 [0.18, 1.91]
Rajter et al	26	173	27	107	10.5%	0.52 [0.29, 0.96]
Shahbaznejad et al	1	35	0	34	1.6%	3.00 [0.12, 76.24]
Soto-Becerra et al	132	561	940	5122	12.6%	1.37 [1.11, 1.68]
Veerapaneni et al	1	50	0	50	1.6%	3.06 [0.12, 76.95]
Total (95% CI)		**1729**		**8096**	**100.0%**	**0.65 [0.42, 1.00]**
Total events	261		1281			

Heterogeneity: Tau² = 0.39; Chi² = 47.24, df = 16 (P < 0.0001); I² = 66%
Test for overall effect: Z = 1.95 (P = 0.05)



Figure 3F: Mortality in hospitalized patients by study design RCTs-Mild-Moderate COVID-19



Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Abd-elsalam et al	3	82	4	82	41.4%	0.74 [0.16, 3.42]
Kirti et al	0	55	4	57	24.6%	0.11 [0.01, 2.04]
Mohan et al	0	100	0	52		Not estimable
Niaee et al	1	103	10	55	34.0%	0.04 [0.01, 0.36]
Shahbaznejad et al	0	28	0	31		Not estimable
Total (95% CI)		**368**		**277**	**100.0%**	**0.18 [0.02, 1.25]**
Total events	4		18			

Heterogeneity: Tau² = 1.80; Chi² = 5.12, df = 2 (P = 0.08); I² = 61%
Test for overall effect: Z = 1.74 (P = 0.08)

Figure 3G: Mortality in hospitalized patients by study design RCTs- Severe/Critical COVID-19



Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Galan et al	12	53	25	115	45.3%	1.05 [0.48, 2.30]
Gonzalez et al	5	36	8	70	19.3%	1.25 [0.38, 4.14]
Hashim et al	2	22	6	22	9.2%	0.27 [0.05, 1.50]
Niaee et al	3	17	1	5	4.3%	0.86 [0.07, 10.67]
Okumus et al	6	30	9	30	19.6%	0.58 [0.18, 1.91]
Shahbaznejad et al	1	7	0	3	2.3%	1.62 [0.05, 51.11]
Total (95% CI)		**165**		**245**	**100.0%**	**0.86 [0.51, 1.45]**
Total events	29		49			

Heterogeneity: Tau² = 0.00; Chi² = 2.94, df = 5 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.56)

Figure 3H: Mortality in hospitalized patients by study design observational studies



Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Ahsan et al	17	110	17	55	16.5%	0.41 [0.19, 0.88]
Budhiraja et al	0	34	103	942	4.0%	0.12 [0.01, 1.93]
Ghooi et al	3	15	77	1020	11.3%	3.06 [0.85, 11.08]
Guzman et al	48	122	39	74	18.6%	0.58 [0.32, 1.04]
Khan et al	1	115	9	133	6.3%	0.12 [0.02, 0.97]
Rajter et al	26	173	27	107	18.4%	0.52 [0.29, 0.96]
Soto-Becerra et al	132	561	940	5122	21.8%	1.37 [1.11, 1.68]
Veerapaneni et al	1	50	0	50	3.1%	3.06 [0.12, 76.95]
Total (95% CI)		**1180**		**7503**	**100.0%**	**0.70 [0.38, 1.30]**
Total events	228		1212			

Heterogeneity: Tau² = 0.44; Chi² = 30.86, df = 7 (P < 0.0001); I² = 77%
Test for overall effect: Z = 1.13 (P = 0.26)

Figure 4 Effect of Ivermectin Monotherapy compared with Placebo/Standard of Care in RCTs as per Cochrane's criteria

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
1.10.1 Mild-Moderate COVID-19						
Abd-elsalam et al	3	82	4	82	25.4%	0.74 [0.16, 3.42]
Chaccour et al	0	12	0	12		Not estimable
Kirti et al	0	55	4	57	6.8%	0.11 [0.01, 2.04]
Lopez-Medina et al	0	200	1	198	5.8%	0.33 [0.01, 8.11]
Mohan et al	0	100	0	52		Not estimable
Vallejos et al	4	250	3	251	26.1%	1.34 [0.30, 6.07]
Subtotal (95% CI)		**699**		**652**	**64.1%**	**0.71 [0.27, 1.87]**
Total events	7		12			
Heterogeneity: Tau² = 0.00; Chi² = 2.59, df = 3 (P = 0.46); I² = 0%						
Test for overall effect: Z = 0.69 (P = 0.49)						
1.10.2 Severe/Critical COVID-19						
Gonzalez et al	5	36	6	37	35.9%	0.83 [0.23, 3.02]
Subtotal (95% CI)		**36**		**37**	**35.9%**	**0.83 [0.23, 3.02]**
Total events	5		6			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.28 (P = 0.78)						
Total (95% CI)		**735**		**689**	**100.0%**	**0.75 [0.35, 1.63]**
Total events	12		18			
Heterogeneity: Tau² = 0.00; Chi² = 2.61, df = 4 (P = 0.62); I² = 0%						
Test for overall effect: Z = 0.72 (P = 0.47)						
Test for subgroup differences: Chi² = 0.04, df = 1 (P = 0.85), I² = 0%						



Figure 5: Meta-analysis for Ivermectin use and need for ICU admission, mechanical ventilation and Adverse events

Figure 5A Need for ICU admission

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Camprubi et al	5	13	9	13	19.7%	0.28 [0.05, 1.41]
Galan et al	15	53	25	115	31.4%	1.42 [0.68, 2.99]
Khan et al	1	115	11	133	15.3%	0.10 [0.01, 0.77]
Kirti et al	5	55	6	57	24.4%	0.85 [0.24, 2.96]
Pott-Junior et al	1	27	1	4	9.1%	0.12 [0.01, 2.36]
Total (95% CI)		**263**		**322**	**100.0%**	**0.48 [0.17, 1.37]**
Total events	27		52			
Heterogeneity: Tau² = 0.77; Chi² = 9.77, df = 4 (P = 0.04); I² = 59%						
Test for overall effect: Z = 1.37 (P = 0.17)						



Figure 5B Sensitivity Analysis excluding Galan et al : Need for ICU admission

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Camprubi et al	5	13	9	13	28.9%	0.28 [0.05, 1.41]
Galan et al	15	53	25	115	0.0%	1.42 [0.68, 2.99]
Khan et al	1	115	11	133	20.3%	0.10 [0.01, 0.77]
Kirti et al	5	55	6	57	40.1%	0.85 [0.24, 2.96]
Pott-Junior et al	1	27	1	4	10.7%	0.12 [0.01, 2.36]
Total (95% CI)		**210**		**207**	**100.0%**	**0.32 [0.11, 0.92]**
Total events	12		27			
Heterogeneity: Tau² = 0.31; Chi² = 4.09, df = 3 (P = 0.25); I² = 27%						
Test for overall effect: Z = 2.12 (P = 0.03)						



Figure 5C Need for Mechanical ventilation

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Abd-elsalam et al	3	82	3	82	4.9%	1.00 [0.20, 5.11]
Cadegiani et al	0	110	9	137	1.6%	0.06 [0.00, 1.06]
Camprubi et al	3	13	5	13	4.5%	0.48 [0.09, 2.65]
Galan et al	12	53	24	115	21.1%	1.11 [0.51, 2.43]
Kirti et al	1	55	5	57	2.7%	0.19 [0.02, 1.70]
Kroleweicki et al	1	30	0	15	1.2%	1.58 [0.06, 41.03]
Lima-Morales et al	8	434	11	287	15.3%	0.47 [0.19, 1.19]
Mohan et al	0	100	0	52		Not estimable
Pott-Junior et al	1	27	1	4	1.4%	0.12 [0.01, 2.36]
Rajter et al	36	173	26	107	39.4%	0.82 [0.46, 1.45]
Shahbaznejad et al	2	35	1	34	2.2%	2.00 [0.17, 23.14]
Vallejos et al	4	250	3	251	5.7%	1.34 [0.30, 6.07]
Total (95% CI)		**1362**		**1154**	**100.0%**	**0.75 [0.52, 1.08]**
Total events	71		88			

Heterogeneity: Tau² = 0.00; Chi² = 9.89, df = 10 (P = 0.45); I² = 0%
Test for overall effect: Z = 1.56 (P = 0.12)



Figure 5D Sensitivity Analysis excluding Galan et al : Need for Mechanical ventilation

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Abd-elsalam et al	3	82	3	82	6.2%	1.00 [0.20, 5.11]
Cadegiani et al	0	110	9	137	2.0%	0.06 [0.00, 1.06]
Camprubi et al	3	13	5	13	5.7%	0.48 [0.09, 2.65]
Galan et al	12	53	24	115	0.0%	1.11 [0.51, 2.43]
Kirti et al	1	55	5	57	3.5%	0.19 [0.02, 1.70]
Kroleweicki et al	1	30	0	15	1.6%	1.58 [0.06, 41.03]
Lima-Morales et al	8	434	11	287	19.3%	0.47 [0.19, 1.19]
Mohan et al	0	100	0	52		Not estimable
Pott-Junior et al	1	27	1	4	1.8%	0.12 [0.01, 2.36]
Rajter et al	36	173	26	107	50.0%	0.82 [0.46, 1.45]
Shahbaznejad et al	2	35	1	34	2.7%	2.00 [0.17, 23.14]
Vallejos et al	4	250	3	251	7.3%	1.34 [0.30, 6.07]
Total (95% CI)		**1309**		**1039**	**100.0%**	**0.68 [0.45, 1.01]**
Total events	59		64			

Heterogeneity: Tau² = 0.00; Chi² = 8.67, df = 9 (P = 0.47); I² = 0%
Test for overall effect: Z = 1.89 (P = 0.06)



Figure 5E Adverse events

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Afsar et al	0	41	0	54		Not estimable
Ahmed et al	0	45	0	23		Not estimable
Babalola et al	0	42	0	20		Not estimable
Biber et al	2	47	1	42	1.1%	1.82 [0.16, 20.85]
Bukhari et al	0	41	0	45		Not estimable
Camprubi et al	3	13	4	13	2.1%	0.68 [0.12, 3.87]
Chaccour et al	5	12	5	12	2.5%	1.00 [0.20, 5.07]
Chowdhury et al	19	60	26	56	11.3%	0.53 [0.25, 1.14]
Espitia-Hernandez et al	3	28	0	7	0.7%	2.06 [0.10, 44.48]
Galan et al	8	53	16	115	7.7%	1.10 [0.44, 2.76]
Gorial et al	0	16	0	71		Not estimable
Huvemec group	0	50	0	50		Not estimable
Kroleweicki et al	13	30	5	15	3.9%	1.53 [0.42, 5.58]
Lopez-Medina et al	156	200	163	198	25.7%	0.76 [0.46, 1.25]
Mahmud et al	9	185	0	180	0.8%	19.43 [1.12, 336.37]
Mohan et al	14	100	6	52	6.2%	1.25 [0.45, 3.47]
Mourya et al	0	50	0	50		Not estimable
Okumus et al	0	30	3	30	0.7%	0.13 [0.01, 2.61]
Pott-Junior et al	7	27	2	4	1.4%	0.35 [0.04, 2.98]
Shahbaznejad et al	0	35	0	34		Not estimable
Vallejos et al	45	250	53	251	31.8%	0.82 [0.53, 1.28]
Veerapaneni et al	8	50	4	50	4.0%	2.19 [0.61, 7.81]
Total (95% CI)		**1405**		**1372**	**100.0%**	**0.87 [0.67, 1.13]**
Total events	292		288			

Heterogeneity: Tau² = 0.00; Chi² = 13.14, df = 13 (P = 0.44); I² = 1%
Test for overall effect: Z = 1.05 (P = 0.30)



Figure 5F Sensitivity Analysis excluding Veerapaneni et al : Adverse events

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Afsar et al	0	41	0	54		Not estimable
Ahmed et al	0	45	0	23		Not estimable
Babalola et al	0	42	0	20		Not estimable
Biber et al	2	47	1	42	1.1%	1.82 [0.16, 20.85]
Bukhari et al	0	41	0	45		Not estimable
Camprubi et al	3	13	4	13	2.2%	0.68 [0.12, 3.87]
Chaccour et al	5	12	5	12	2.5%	1.00 [0.20, 5.07]
Chowdhury et al	19	60	26	56	11.6%	0.53 [0.25, 1.14]
Espitia-Hernandez et al	3	28	0	7	0.7%	2.06 [0.10, 44.48]
Galan et al	8	53	16	115	7.8%	1.10 [0.44, 2.76]
Gorial et al	0	16	0	71		Not estimable
Huvemec group	0	50	0	50		Not estimable
Kroleweicki et al	13	30	5	15	4.0%	1.53 [0.42, 5.58]
Lopez-Medina et al	156	200	163	198	27.0%	0.76 [0.46, 1.25]
Mahmud et al	9	185	0	180	0.8%	19.43 [1.12, 336.37]
Mohan et al	14	100	6	52	6.3%	1.25 [0.45, 3.47]
Mourya et al	0	50	0	50		Not estimable
Okumus et al	0	30	3	30	0.7%	0.13 [0.01, 2.61]
Pott-Junior et al	7	27	2	4	1.4%	0.35 [0.04, 2.98]
Shahbaznejad et al	0	35	0	34		Not estimable
Vallejos et al	45	250	53	251	33.8%	0.82 [0.53, 1.28]
Veerapaneni et al	8	50	4	50	0.0%	2.19 [0.61, 7.81]
Total (95% CI)		**1355**		**1322**	**100.0%**	**0.84 [0.65, 1.08]**
Total events	284		284			

Heterogeneity: Tau² = 0.00; Chi² = 11.03, df = 12 (P = 0.53); I² = 0%
Test for overall effect: Z = 1.35 (P = 0.18)



Figure 6: Meta-analysis for Ivermectin use and need for Viral Clearance, Time to achieve viral clearance, Need for hospitalization and Duration of hospital stay

Figure 6A Viral Clearance

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Ahmed et al	31	45	9	23	6.0%	3.44 [1.21, 9.83]
Aref et al	54	57	43	57	5.5%	5.86 [1.58, 21.71]
Biber et al	40	47	29	42	6.0%	2.56 [0.91, 7.22]
Bukhari et al	37	41	20	45	5.7%	11.56 [3.53, 37.91]
Camprubi et al	8	13	9	13	5.0%	0.71 [0.14, 3.61]
Chaccour et al	0	12	0	12		Not estimable
Chowdhury et al	60	60	54	56	2.8%	5.55 [0.26, 118.18]
Elalfy et al	55	62	7	51	5.9%	49.39 [16.11, 151.39]
Espitia-Hernandez et al	28	28	0	7	2.0%	855.00 [15.63, 46756.26]
Kirti et al	13	55	18	57	6.3%	0.67 [0.29, 1.55]
Kishoria et al	8	19	6	13	5.3%	0.85 [0.20, 3.51]
Loué et al	10	10	15	15		Not estimable
Mahmud et al	169	183	144	180	6.6%	3.02 [1.57, 5.82]
Mohan et al	29	72	16	42	6.4%	1.10 [0.50, 2.39]
Mourya et al	45	50	3	50	5.2%	141.00 [31.82, 624.74]
Okumus et al	14	16	3	8	4.2%	11.67 [1.49, 91.54]
Podder et al	18	20	19	20	3.5%	0.47 [0.04, 5.69]
Pott-Junior et al	17	27	2	4	4.1%	1.70 [0.21, 14.02]
Rahman et al	167	200	163	200	6.7%	1.15 [0.69, 1.93]
Samaha et al	12	50	0	50	3.1%	32.79 [1.88, 571.25]
Vallejos et al	212	250	221	251	6.7%	0.76 [0.45, 1.27]
Veerapaneni et al	9	10	9	10	3.0%	1.00 [0.05, 18.57]
Total (95% CI)		**1327**		**1206**	**100.0%**	**3.52 [1.81, 6.86]**
Total events	1036		790			

Heterogeneity: Tau² = 1.65; Chi² = 126.69, df = 19 (P < 0.00001); I² = 85%
Test for overall effect: Z = 3.70 (P = 0.0002)



Figure 6B Time to achieve viral clearance

Study or Subgroup	Ivermectin Mean	Ivermectin SD	Ivermectin Total	No Ivermectin Mean	No Ivermectin SD	No Ivermectin Total	Weight	Mean Difference IV, Random, 95% CI
Ahmed et al (IVM)	9.7	4.5	22	12.7	3.35	23	12.3%	-3.00 [-5.33, -0.67]
Aref et al	8.3	2.8	57	12.9	4.3	57	12.8%	-4.60 [-5.93, -3.27]
Babalola et al	5.33	3.12	42	9.15	7.42	20	11.6%	-3.82 [-7.21, -0.43]
Cadegiani et al	16.036	6.5	110	22.2	6	137	12.7%	-6.16 [-7.74, -4.59]
Chowdhury et al	8.93	1.29	60	9.26	2.27	54	13.0%	-0.33 [-1.02, 0.36]
Gorial et al	8	4.06	16	12.33	3.78	71	12.4%	-4.33 [-6.51, -2.15]
Khan et al	4.6	1.5	115	14.6	3.75	133	13.0%	-10.00 [-10.69, -9.31]
Pott-Junior et al	5.16	2.74	27	5.67	2.18	4	12.3%	-0.51 [-2.88, 1.86]
Total (95% CI)			**449**			**499**	**100.0%**	**-4.12 [-7.59, -0.65]**

Heterogeneity: Tau² = 24.09; Chi² = 396.19, df = 7 (P < 0.00001); I² = 98%
Test for overall effect: Z = 2.33 (P = 0.02)



Figure 6C Need for hospitalization

Study or Subgroup	Ivermectin Events	Ivermectin Total	No Ivermectin Events	No Ivermectin Total	Weight	Odds Ratio M-H, Random, 95% CI
Biber et al	1	47	3	42	8.4%	0.28 [0.03, 2.83]
Cadegiani et al	0	110	27	137	6.2%	0.02 [0.00, 0.30]
Lima-Morales et al	40	434	89	287	27.8%	0.23 [0.15, 0.34]
Mahmud et al	58	183	69	180	27.6%	0.75 [0.48, 1.15]
Samaha et al	0	50	3	50	5.6%	0.13 [0.01, 2.67]
Vallejos et al	14	250	21	251	24.3%	0.65 [0.32, 1.31]
Total (95% CI)		**1074**		**947**	**100.0%**	**0.34 [0.16, 0.75]**
Total events	113		212			

Heterogeneity: Tau² = 0.54; Chi² = 23.10, df = 5 (P = 0.0003); I² = 78%
Test for overall effect: Z = 2.66 (P = 0.008)



Figure 6D Duration of hospital stay

Study or Subgroup	Ivermectin Mean	Ivermectin SD	Ivermectin Total	No Ivermectin Mean	No Ivermectin SD	No Ivermectin Total	Weight	Mean Difference IV, Random, 95% CI
Abd-elsalam et al	8.82	4.94	82	10.97	5.28	82	11.1%	-2.15 [-3.72, -0.58]
Ahmed et al (IVM)	9.6	4.5	22	9.7	3.35	23	10.2%	-0.10 [-2.43, 2.23]
Gonzalez et al (IVM vs placebo)	7	5.4	36	5.33	2.3	37	10.7%	1.67 [-0.24, 3.58]
Gorial et al	7.62	2.75	16	13.22	5.9	71	10.7%	-5.60 [-7.52, -3.68]
Khan et al	8.66	2.25	115	15.33	5.24	133	11.6%	-6.67 [-7.65, -5.69]
Niaee et al	6.93	2.74	120	8.53	3.92	60	11.5%	-1.60 [-2.71, -0.49]
Rajter et al	8.1	6.95	173	7	4.5	107	11.3%	1.10 [-0.24, 2.44]
Shahbaznejad et al	6.9	3.1	35	8.3	3.3	34	11.2%	-1.40 [-2.91, 0.11]
Veerapaneni et al	6.67	2.01	50	7.89	2.35	50	11.7%	-1.22 [-2.08, -0.36]
Total (95% CI)			**649**			**597**	**100.0%**	**-1.80 [-3.69, 0.08]**

Heterogeneity: Tau² = 7.67; Chi² = 141.10, df = 8 (P < 0.00001); I² = 94%
Test for overall effect: Z = 1.88 (P = 0.06)